High Level Group on Innovation and Provision of Medicines
In 2000, the report "Global Competitiveness in Pharmaceuticals - a European Perspective" [347 KB] raised a concern over the actual competitiveness of the European Pharmaceutical Industry compared with that of the US model.
The conclusion of the report was that "Europe as a whole is lagging behind in its ability to generate, organise, and sustain innovation processes that are increasingly expensive and organisationally complex".
In response to this issue, the European Commission, represented by Commissioners Erkki Liikanen and David Byrne, created in 2001 the High Level Group on Innovation and the Provision of Medicines, then called G-10 Medicines. The G-10 was composed of ten selected private and governmental health stakeholders in Europe. The selection process was carried out by the European Commission, which was concerned that the group reflected as many interests as possible in order to obtain a valuable contribution from every participant.
The G-10 was charged with exploring different ways of enhancing the pharmaceutical industry's competitiveness in Europe, without affecting the satisfactory and affordable delivery of healthcare services to the population. Three broad areas of study were taken into account: innovation; provision of medicines to patients; market structure in Europe, competition and regulation.
The Group set itself a target of one year within which to prepare a final report for Commissioner President Prodi. The G10 report [503 KB] , issued in 2002, contains a total of fourteen wide-ranging recommendations as a result of the consensus reached among the members' Group.
In response to this report, the European Commission adopted on 1 July 2003 the Communication, "A stronger European-based pharmaceutical industry for the benefit of the patient - a call for action " which outlines the Commission's proposals for advancing the G10 recommendations.